Brain disease researchers turn to body fluid tests for faster drug development

A new editorial highlights how analyzing cerebrospinal fluid and blood biomarkers could accelerate neurodegenerative disease research and drug trials. For pharmaceutical companies and healthcare systems, this approach promises to identify disease progression earlier and validate new treatments more efficiently than traditional methods.

Originaltitel: Editorial: Body fluid biomarkers in neurodegenerative studies: Novel insights into pathophysiology to support clinical practice and drug development